Global Immuno Oncology Assays Market Size, by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer, Other Cancers), Applications (Research, Clinical Diagnostics), Region and Forecast, 2018 to 2028
Aug 2020
Total Pages: 150
Choose License Type
The global immuno oncology assays market was valued at USD 3.6 billion in 2019 and is expected to grow at a CAGR of 12.4% over the forecast period. With the population 's rising average life expectancy, 14 million new cases of cancer are reported worldwide globally. The following examples are intended to demonstrate the immense power of treatment options for immune oncology in addressing these cases.
.png "Global Immuno Oncology Assays Market by Region 2018-2028 (USD Billion)")
The global immuno oncology assays market is categorized based on product, technology, indication, and applications. Region wise, North America was the largest market in 2018; however, Asia Pacific is expected to be the fastest growing region by 2028, with a CAGR of over 13%.
Key players serving the global immuno oncology assays market include F. Hoffmann-La Roche Ltd., Abbott, Merck KGaA, Agilent Technologies, Thermo Fisher Scientific, Inc., QIAGEN, bioMérieux SA, Illumina, Inc., PerkinElmer Inc., Randox Laboratories Ltd. among other prominent players.
Key segments of the global immuno oncology assays market
Product Overview, 2018-2028 (USD Billion)
- Consumables
- Software
Technology Overview, 2018-2028 (USD Billion)
- Immunoassay
- Flow Cytometry
- PCR
- Next Generation Sequencing
Indication Overview, 2018-2028 (USD Billion)
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Bladder Cancer
- Other Cancers
Applications Overview, 2018-2028 (USD Billion)
- Research
- Clinical Diagnostics
Regional Overview, 2018-2028 (USD Billion)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Rest of Middle East and Africa
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global Immuno Oncology Assays industry
- The overall segmentation of Immuno Oncology Assays market, especially key segments are thoroughly studied.
- Presence of major players and their wide product portfolio across developed countries is anticipated to further boost the growth of Immuno Oncology Assays market
What does the report include?
- The study on the global immuno oncology assays market includes analysis of qualitative market indicators such as drivers, restraints, challenges and opportunities
- Additionally, the market competition has been evaluated using the Porter’s five forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of applications, product, technology and end user. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the considered segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global immuno oncology assays market is suitable for all the players across the value chain including raw material suppliers, immuno oncology assays providers, medical device manufacturers, distributors, suppliers and retailers
- Venture capitalists and investors looking for more information on the future outlook of the global immuno oncology assays market
Consultants, analysts, researchers, and academicians looking for insights shaping the global immuno oncology assays market
All the researchers across the globe are in quest of researching modern techniques for effective cancer care such as immuno-oncology, which use the body's natural defenses to kill & eliminate cancer cells. Due to their specificity, adaptability and durability, immuno-oncology has become an exciting new approach to cancer treatment over the past decade. However, many challenges remain to the development of new immunotherapies. In this highly complex tumor microenvironment, proper instruments are needed to accurately map the diverse interactions between immune cells and tumor cells. In Western developed countries tumor disorders are one of the most frequent causes of death. Immune oncological strategies help accelerate new rates of curative cancer diagnosis, which can also contribute to certain forms of cancer being eradicated, but creation of such techniques involves precise, responsive bioanalytical methods which specialized oncology assays.
The therapeutic cancer world is now experiencing a fascinating transition, as the scope of accessible drugs has extended to a number of modern molecularly based therapies beyond chemotherapy. Although traditional therapeutics attacked all cell types in previous years, new treatment approaches are now aimed at tumor cells. Although medications paired with specific antibodies (ADC, Antibody-Drug conjugates) carry the tumor-killing agent to its position primarily to remove tumor cells, new immune oncological therapeutic options manipulate the immune system to eliminate cancer cells.
The global immuno oncology assays market has been segmented based on product, technology, indication, applications. One the basis of product, the global market is bifurcated into software & consumables. In the year 2019, consumables segment accounted for the majority of the market share and is projected to witness highest CAGR over the forecast period from 2020 to 2028. The market dominancy is attributed to growing usage of reagents in several oncology therapeutic treatments coupled with rising R&D on cancer immunotherapy.
Based on the application segment, the global immuno-oncology assays market is sub-segmented into research & clinical diagnostics. In the year 2019, research segment held the majority of the market share owing to growing prominence of biomarker-based drug development coupled with the emergence of cancer immunotherapy. The global immuno oncology assays market for research-based applications is projected to witness highest CAGR over the forecast period from 2020 to 2028.
Based on regions, the global immuno oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The introduction of experimental immunotherapies in cancer therapy has significantly changed the oncology sector environment. New advancements in checkpoint inhibitor therapies, tumor-infiltrating lymphocyte therapies, T-cell receptor chimeric antigen therapies, and cancer vaccines have shown great potential for major improvements in cancer treatments. Immunotherapy works on distinct immune response measures to improve the body's innate capacity to detect, track, and kill cancer cells. Combination therapies with immunotherapies and other modalities aim to activate immune response, decrease immunosuppression, and target signaling and resistance pathways in order to provide a more durable , long-lasting treatment as compared to traditional cancer therapies and immunotherapies.
North America currently holds majority of the market share followed by Europe, while Asia Pacific region is anticipated witness highest growth rate over the forecast period. Cancer is the second leading cause of death in the United States and continues to significantly affect populations worldwide. Traditional therapies for cancer have been based on the patient’s tumor type and stage with treatment variations of surgery, radiation, and/or chemotherapy. However, even with the advancements in medicine, many patients progress and succumb to cancer. A relatively new field of cancer therapy includes immunotherapy. Immunotherapy aims to harness the immune system’s ability to recognize, target, and destroy cancerous cells
The global immuno oncology assays market was valued at USD 3.6 billion in 2019 and is expected to grow at a CAGR of 12.4% over the forecast period. With the population 's rising average life expectancy, 14 million new cases of cancer are reported worldwide globally. The following examples are intended to demonstrate the immense power of treatment options for immune oncology in addressing these cases.
The global immuno oncology assays market is categorized based on product, technology, indication, and applications. Region wise, North America was the largest market in 2018; however, Asia Pacific is expected to be the fastest growing region by 2028, with a CAGR of over 13%.
Key players serving the global immuno oncology assays market include F. Hoffmann-La Roche Ltd., Abbott, Merck KGaA, Agilent Technologies, Thermo Fisher Scientific, Inc., QIAGEN, bioMérieux SA, Illumina, Inc., PerkinElmer Inc., Randox Laboratories Ltd. among other prominent players.
Key segments of the global immuno oncology assays market
Product Overview, 2018-2028 (USD Billion)
- Consumables
- Software
Technology Overview, 2018-2028 (USD Billion)
- Immunoassay
- Flow Cytometry
- PCR
- Next Generation Sequencing
Indication Overview, 2018-2028 (USD Billion)
- Lung Cancer
- Colorectal Cancer
- Melanoma
- Bladder Cancer
- Other Cancers
Applications Overview, 2018-2028 (USD Billion)
- Research
- Clinical Diagnostics
Regional Overview, 2018-2028 (USD Billion)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Rest of Middle East and Africa
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global Immuno Oncology Assays industry
- The overall segmentation of Immuno Oncology Assays market, especially key segments are thoroughly studied.
- Presence of major players and their wide product portfolio across developed countries is anticipated to further boost the growth of Immuno Oncology Assays market
What does the report include?
- The study on the global immuno oncology assays market includes analysis of qualitative market indicators such as drivers, restraints, challenges and opportunities
- Additionally, the market competition has been evaluated using the Porter’s five forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of applications, product, technology and end user. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the considered segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global immuno oncology assays market is suitable for all the players across the value chain including raw material suppliers, immuno oncology assays providers, medical device manufacturers, distributors, suppliers and retailers
- Venture capitalists and investors looking for more information on the future outlook of the global immuno oncology assays market
Consultants, analysts, researchers, and academicians looking for insights shaping the global immuno oncology assays market
Chapter 1. Introduction
1.1. Introduction to the Study
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
Chapter 2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.3. Primary Sources
2.4. Secondary Sources
2.5. Market Size Estimation
2.6. Market Forecast
2.7. Data Triangulation
2.8. Assumptions and Limitations
Chapter 3. Market Outlook
3.1. Introduction
3.2. Macroeconomic Indicators
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints
3.3.3. Opportunities
3.3.4. Challenges
3.4. Porter’s Five Forces Analysis
3.5. PESTLE Analysis
3.6. COVID-19 Impact Analysis
Chapter 4. Global Immuno Oncology Assays Market by Product, 2018-2028 (USD Billion)
4.1.1. Consumables
4.1.2. Software
Chapter 5. Global Immuno Oncology Assays Market by Technology, 2018-2028 (USD Billion)
5.1.1. Immunoassay
5.1.2. Flow Cytometry
5.1.3. PCR
5.1.4. Next Generation Sequencing
Chapter 6. Global Immuno Oncology Assays Market by Indication, 2018-2028 (USD Billion)
6.1.1. Lung Cancer
6.1.2. Colorectal Cancer
6.1.3. Other Cancers
Chapter 7. Global Immuno Oncology Assays Market by Applications, 2018-2028 (USD Billion)
7.1.1. Research
7.1.2. Clinical Diagnostics
Chapter 8. Global Immuno Oncology Assays Market by Region, 2018-2028 (USD Billion)
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. UK
8.2.3. France
8.2.4. Spain
8.2.5. Rest of Europe
8.3. Asia Pacific
8.3.1. Japan
8.3.2. China
8.3.3. India
8.3.4. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East and Africa
8.5.1. GCC
8.5.2. Rest of Middle East and Africa
Chapter 9. Company Profiles
9.1. F. Hoffmann-La Roche Ltd.
9.1.1. Overview
9.1.2. Products and Services Portfolio
9.1.3. Recent Initiatives
9.1.4. Company Financials
9.2. Abbott
9.2.1. Overview
9.2.2. Products and Services Portfolio
9.2.3. Recent Initiatives
9.2.4. Company Financials
9.3. Merck KGaA
9.3.1. Overview
9.3.2. Products and Services Portfolio
9.3.3. Recent Initiatives
9.3.4. Company Financials
9.4. Agilent Technologies
9.4.1. Overview
9.4.2. Products and Services Portfolio
9.4.3. Recent Initiatives
9.4.4. Company Financials
9.5. Thermo Fisher Scientific, Inc.
9.5.1. Overview
9.5.2. Products and Services Portfolio
9.5.3. Recent Initiatives
9.5.4. Company Financials
9.6. QIAGEN
9.6.1. Overview
9.6.2. Products and Services Portfolio
9.6.3. Recent Initiatives
9.6.4. Company Financials
9.7. bioMérieux SA
9.7.1. Overview
9.7.2. Products and Services Portfolio
9.7.3. Recent Initiatives
9.7.4. Company Financials
9.8. Illumina, Inc.
9.8.1. Overview
9.8.2. Products and Services Portfolio
9.8.3. Recent Initiatives
9.8.4. Company Financials
9.9. PerkinElmer Inc.
9.9.1. Overview
9.9.2. Products and Services Portfolio
9.9.3. Recent Initiatives
9.9.4. Company Financials
9.10. Randox Laboratories Ltd.
9.10.1. Overview
9.10.2. Products and Services Portfolio
9.10.3. Recent Initiatives
9.10.4. Company Financials
Chapter 10. Appendix
10.1. Primary Research Approach
10.1.1. Primary Interview Participants
10.1.2. Primary Interview Summary
10.2. Questionnaire
10.3. Related Reports
10.3.1. Published
10.3.2. Upcoming